B+
Bull case
25%
Probability
Target price
$20.00
Analysis reference price unavailable
Analysis 2026-11-04 · RankAlpha Sentiment Codex
SHC
Sotera HealthBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Q3 adjusted EPS of $0.29 exceeded the approximately $0.27 consensus, and revenue of $324.9 million exceeded the approximately $319.8 million consensus. Sterigenics and Nelson Labs grew, operating cash flow was $111 million, and net leverage improved to 2.9x.
Posture
Constructive
Lead driver
Value
What changed
1 setup hits (3d) with net bearish as of 2026-11-04.
What can break
Ethylene-oxide litigation, regulation, and EO or Co-60 supply disruptions remain disclosed risks. Company release
Momentum
58
Value
63
Sentiment
56
Setup hits (3d)
1 · Net Bearish
AI TargetsBase $16.00 · Bull $20.00 · Bear $12.00Analysis 2026-11-04; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-11-04 • Vendor: Data Vendor v1
Scores
As of 2026-11-04 • Model: HYBRID_IC_RP
AI Memo
As of 2026-11-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-11-04
Investment thesis
As of 2026-11-04
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-11-04. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bearish
Target $21.44
Why
Momentum58 · Δ7d -37.9
Value63 · Δ7d +0.7
Sentiment56 · Δ7d +18.7
So what
Strength-led posture (Net Bearish). Favor watchlist adds and disciplined entries.
Confirming evidence
- • 1 setup hits (3d) with net bearish as of 2026-11-04.
- • Value remains the lead driver in the composite, 7D delta +0.7.
Contradictions & invalidation
- • Ethylene-oxide litigation, regulation, and EO or Co-60 supply disruptions remain disclosed risks. Company release
- • European medical-device customer softness could persist beyond Q4; management has not provided a quantified 2027 demand outlook. Call transcript
- • The beat did not translate into higher FY2026 guidance.
Catalyst clock
2026-12-31
European medical-device demand weakness
Lead driver: Value · See fundamentals
Momentum
58
18% active weight
Current posture
7d trendSoftening
Δ7d
-37.9
Δ21d
-22.4
Value
63
43% active weight
Current posture
7d trendFlat
Δ7d
+0.7
Δ21d
+0.3
Sentiment
56
39% active weight
Current posture
7d trendImproving
Δ7d
+18.7
Δ21d
+17.3
Why this grade
Composite grade B. Momentum 58.4 / Value 63.1 / Sentiment 55.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-11-04. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$16.00
Analysis reference price unavailable
Analysis 2026-11-04 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-11-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-11-04
Fundamentals (TTM)
As of 2026-11-04
Market Cap
$4.68B
Beta
1.82
Shares Out
285.38M
P/E (TTM)
94.8
P/S (TTM)
4.52
P/FCF (TTM)
60.02
Rev YoY
+9.2%
EPS YoY
+567.4%
Gross Margin
+54.0%
Op Margin
+36.9%
Net Debt
$1.93B
Current Ratio
2.80
As of 2026-11-04 • Updated nightlySource: Internal modelMethods & Data